- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
ACCC Launches ICLIO for Community Oncologists
ICLIO promises to guide oncologists in community care practices to navigate the growing field of immuno-oncology.
Immuno-oncology, which has transformed the cancer treatment landscape, is rapidly being adopted into clinical practice and yielding promising results in oncology. However, questions about indications, biomarkers, cost of care, adverse effects, and reimbursement, remain. To help guide oncologists in community care practices to navigate this growing field, The Association of Community Cancer Centers has launched the Institute for Clinical Immuno-Oncology (ICLIO). Lee S. Schwartzberg, MD, FACP, chair of ICLIO had introduced ICLIO to our managed care readers through an article in Evidence-Based Oncology back in February.
ICLIO is open to all ACCC members, which includes more than 2000 cancer programs and 20,000 providers nationwide. ACCC estimates that nearly 60% of all cancer patients in the United States are treated by someone in the ACCC network.
Read the press release: http://prn.to/1dKhTgN
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Prediagnosis Diet Improves Survival in Black Women With Deadly Ovarian Cancer
October 24th 2024Moderate prediagnosis adherence to dietary guidelines was associated with improved survival rates among Black women with high-grade serous ovarian cancer, the most common and lethal type of ovarian cancer.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
Rozanolixizumab Effective in Patients with MuSK MG, Analysis Shows
October 23rd 2024A new subgroup analysis of patients with muscle-specific tyrosine kinase (MuSK) autoantibody-positive (Ab+) myasthenia gravis (MG) shows rozanolixizumab (Rystiggo) contributes to meaningful symptom improvement.
Read More
